1093 — CSPC PHARMACEUTICAL Share News
0.000.00%
Last trade - 00:00- HK$96.15bn
- HK$77.27bn
- CNY26.01bn
Brief: CSPC Pharmaceutical Says Paclitaxel Protein-Bound Particles Gets Clinical Trial Approval In U.S.
Brief: CSPC Pharmaceutical Appoints Zhang Yiwei As Executive Director
Brief: CSPC Pharmaceutical Disposes 30.0704% Equity Interest In Beijing Guoxin Huijin
Brief: CSPC Pharmaceutical Says Ropivacaine Long-Acting Injection Approved For Clinical Trials In China
Brief: CSPC Pharmaceutical Obtains FDA Approval For SYH2082 Clinical Trial
Asian investment banking is at an inflection point
CSPC Pharmaceutical jumps most in eight months on hypertension drug approval
Brief: Cspc Pharmaceutical Says Clevidipine Injectable Emulsion Approved In China
Asian investment banking is at an inflection point
AstraZeneca escalates Big Pharma’s China land grab
AstraZeneca escalates Big Pharma’s China land grab
UK Stocks-Factors to watch on January 30 (updated)
UK Stocks-Factors to watch on January 30
China's CSPC Pharmaceutical signs deal with AstraZeneca for weight loss therapy (updated)
China's CSPC Pharmaceutical inks deal with AstraZeneca for weight loss therapy
Brief: CSPC Pharmaceutical Group Enters Strategic Collaboration And License Agreement With Astrazeneca
Brief: CSPC Pharmaceutical Says SYS6055 Injection Approved For Clinical Trials In China
Brief: CSPC Pharmaceutical Forecasts FY Net Loss Attributable For CSPC Innovation Pharmaceutical
Brief: CSPC Pharmaceutical Says SYH2072 Tablets Obtain U.S. FDA Approval For Clinical Trials